Shangli Cai

4.6k total citations · 2 hit papers
110 papers, 1.9k citations indexed

About

Shangli Cai is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shangli Cai has authored 110 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 48 papers in Cancer Research. Recurrent topics in Shangli Cai's work include Cancer Genomics and Diagnostics (35 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Lung Cancer Treatments and Mutations (23 papers). Shangli Cai is often cited by papers focused on Cancer Genomics and Diagnostics (35 papers), Cancer Immunotherapy and Biomarkers (35 papers) and Lung Cancer Treatments and Mutations (23 papers). Shangli Cai collaborates with scholars based in China, United States and Hong Kong. Shangli Cai's co-authors include Qiang Gao, Jia Fan, Yu Xu, Yuzi Zhang, Zhijie Wang, Fan Zhang, Chengcheng Li, Zijian Yang, Xuelian Ren and Xiaoying Wang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Chemistry.

In The Last Decade

Shangli Cai

99 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma

2023 354 citations Zijian Yang, Cong Yan et al. Nature Metabolism profile →
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer

2019 249 citations Jianchun Duan, Xiaochen Zhao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shangli Cai China	21	990	615	548	544	267	110	1.9k
Monique B. Nilsson United States	25	1.2k 1.2×	1.2k 2.0×	807 1.5×	553 1.0×	273 1.0×	66	2.5k
Helen Wong United Kingdom	24	887 0.9×	971 1.6×	278 0.5×	647 1.2×	126 0.5×	68	2.2k
Ken Op de Beeck Belgium	29	738 0.7×	1.1k 1.9×	430 0.8×	372 0.7×	294 1.1×	77	2.2k
Yanxin Luo China	26	892 0.9×	865 1.4×	361 0.7×	491 0.9×	123 0.5×	88	2.0k
Wenjun Zhou China	19	799 0.8×	927 1.5×	818 1.5×	194 0.4×	219 0.8×	56	2.0k
Ralph Fritsch Germany	23	678 0.7×	903 1.5×	292 0.5×	429 0.8×	217 0.8×	67	1.8k
István Kenessey Hungary	25	766 0.8×	769 1.3×	322 0.6×	437 0.8×	154 0.6×	118	2.0k
Roberto Salgado Belgium	13	893 0.9×	504 0.8×	215 0.4×	356 0.7×	271 1.0×	35	1.5k
Tetsu Hayashida Japan	22	682 0.7×	730 1.2×	265 0.5×	457 0.8×	112 0.4×	101	1.6k
Eric J. Kort United States	26	606 0.6×	1.3k 2.1×	583 1.1×	474 0.9×	106 0.4×	55	2.4k

Countries citing papers authored by Shangli Cai

Since Specialization

Citations

This map shows the geographic impact of Shangli Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shangli Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shangli Cai more than expected).

Fields of papers citing papers by Shangli Cai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shangli Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shangli Cai. The network helps show where Shangli Cai may publish in the future.

Co-authorship network of co-authors of Shangli Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Shangli Cai. A scholar is included among the top collaborators of Shangli Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shangli Cai. Shangli Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Shen, Peng Cui, Lei Zhang, et al.. (2025). CDKN1A and cellular senescence are associated with immune resistance in advanced lung adenocarcinoma. Clinical and Experimental Medicine. 26(1). 14–14.

Feng, Zheng, Huijuan Ge, Jingshu Wang, et al.. (2025). Performance of Liquid Biopsy‐Based Multi‐Omics Biomarkers for Early Detection of Gynecological Malignancies: A Prospective Study (PERCEIVE‐I). Advanced Science. 12(20). e2401760–e2401760. 1 indexed citations

Dong, Xiaochuan, Yanyan Xie, Meng‐Jiang He, et al.. (2025). Pan-gastrointestinal adenocarcinoma analysis uncovers the prognostic and immune correlates of ferroptosis-related genes. Translational Gastroenterology and Hepatology. 10. 7–7.

Li, Huijun, Jingjing Liu, Liang Zhang, et al.. (2024). Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC. Journal for ImmunoTherapy of Cancer. 12(11). e009693–e009693. 2 indexed citations

Sun, Xiaofeng, Hao Song, Xiaoran Sun, et al.. (2024). A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma. Cancer Investigation. 42(3). 226–242.

Sun, Xiaoran, Guoqiang Wang, Wenxian Wang, et al.. (2024). A differentially-methylated-region signature predicts the recurrence risk for patients with early stage lung adenocarcinoma. Aging. 16(21). 13323–13339.

He, Yuming, Fanqi Meng, Jing Zhao, et al.. (2024). The prognostic significance and clinical relevance of stem cell characteristic in bladder cancer. Heliyon. 10(3). e24858–e24858. 1 indexed citations

Yang, Jian, Haoran Li, Di Peng, et al.. (2024). Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer. Cancer Research and Treatment. 56(4). 1183–1196. 4 indexed citations

Guo, Peng, Yujiao Lu, Ke Liang, et al.. (2023). A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma. Pathology & Oncology Research. 29. 1610819–1610819. 3 indexed citations

10.

Yang, Zijian, Cong Yan, Jiaqiang Ma, et al.. (2023). Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma. Nature Metabolism. 5(1). 61–79. 354 indexed citations breakdown →

11.

Liu, Yutao, Jing Zhao, Yanan Wang, et al.. (2023). IMPACT: A web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers. Clinical and Translational Medicine. 13(9). e1354–e1354. 5 indexed citations

12.

Fan, Zhongqi, Yutao Liu, Chengcheng Li, et al.. (2023). T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis. iScience. 27(1). 108701–108701. 8 indexed citations

13.

Han, Sujun, Taoping Shi, Feiya Yang, et al.. (2023). Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer. Journal of Translational Medicine. 21(1). 194–194. 6 indexed citations

14.

Liu, Kan, Yan Huang, Yu Xu, et al.. (2023). BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. Cancer Immunology Immunotherapy. 72(8). 2557–2572. 8 indexed citations

15.

Zhang, Yongchang, Rui Han, Yubo Wang, et al.. (2022). The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer. Cancer Medicine. 12(5). 5603–5614. 4 indexed citations

16.

Zhao, Yang, C. Xu, Jing Zhao, et al.. (2022). DNA Damage Response Gene-Based Subtypes Associated With Clinical Outcomes in Early-Stage Lung Adenocarcinoma. Frontiers in Molecular Biosciences. 9. 901829–901829. 3 indexed citations

17.

Xing, Puyuan, Fan Zhang, Guoqiang Wang, et al.. (2019). Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. Journal for ImmunoTherapy of Cancer. 7(1). 341–341. 141 indexed citations

18.

Sun, Danyang, Junxun Ma, Jinliang Wang, et al.. (2019). Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunology Immunotherapy. 68(9). 1527–1535. 39 indexed citations

19.

Cui, Pengfei, Zhefeng Liu, Guoqiang Wang, et al.. (2018). Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study. Cancer Medicine. 7(8). 4115–4120. 90 indexed citations

20.

Zhuang, Wu, Junxun Ma, Xudong Chen, et al.. (2018). The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. Journal of Cancer. 9(13). 2302–2307. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact